Equities research analysts expect that Lipocine Inc. (NASDAQ:LPCN) will report ($0.33) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Lipocine’s earnings, with estimates ranging from ($0.38) to ($0.29). Lipocine reported earnings of ($0.32) per share in the same quarter last year, which indicates a negative year over year growth rate of 3.1%. The business is expected to report its next earnings report on Tuesday, August 8th.

According to Zacks, analysts expect that Lipocine will report full year earnings of ($1.16) per share for the current financial year, with EPS estimates ranging from ($1.87) to ($0.73). For the next year, analysts forecast that the business will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.53) to $0.25. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Lipocine.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.04.

LPCN has been the topic of a number of recent analyst reports. Roth Capital set a $38.00 price objective on Lipocine and gave the company a “buy” rating in a report on Tuesday, June 20th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Lipocine in a report on Wednesday, April 26th. Finally, Canaccord Genuity set a $10.00 price objective on Lipocine and gave the company a “buy” rating in a report on Monday, April 24th.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/20/0-33-earnings-per-share-expected-for-lipocine-inc-nasdaqlpcn-this-quarter.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LPCN. Ameriprise Financial Inc. boosted its stake in shares of Lipocine by 99.4% in the first quarter. Ameriprise Financial Inc. now owns 131,600 shares of the specialty pharmaceutical company’s stock worth $513,000 after buying an additional 65,600 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Lipocine by 7.1% in the first quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock worth $362,000 after buying an additional 6,191 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock worth $229,000 after buying an additional 12,518 shares during the period. Finally, KCG Holdings Inc. boosted its stake in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 7,219 shares during the period. Institutional investors and hedge funds own 38.55% of the company’s stock.

Lipocine (NASDAQ:LPCN) traded down 0.86% during midday trading on Thursday, reaching $4.63. 130,005 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $4.03 and a 200 day moving average price of $3.87. Lipocine has a 52 week low of $3.03 and a 52 week high of $5.90. The company’s market cap is $89.18 million.

About Lipocine

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get a free copy of the Zacks research report on Lipocine (LPCN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.